TaiMed Biologics Total Liabilities
TaiMed Biologics total liabilities. Based on the latest financial reports, TaiMed Biologics (4147) has total liabilities worth NT$824.49 Million TWD (≈ $25.98 Million USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check TaiMed Biologics liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of TaiMed Biologics (2009–2025)
Total liabilities of TaiMed Biologics from 2009 to 2025. This chart illustrates how TaiMed Biologics's total liabilities have evolved over time, based on quarterly financial data. Explore long-term investment intensity of TaiMed Biologics to see how much of total assets are deployed in long-term investments.
TaiMed Biologics Competitors by Total Liabilities
The table below lists competitors of TaiMed Biologics ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Aberdeen Standard Global Infrastructure Income Fund
NYSE:ASGI
|
USA | $4.35 Million |
|
Studio Dragon Corporation
KQ:253450
|
Korea | ₩234.22 Billion |
|
Gansu Yatai Industrial Development Co Ltd
SHE:000691
|
China | CN¥548.96 Million |
|
COINSHARES I. LS-000247
F:3TW
|
Germany | €5.77 Billion |
|
Zhejiang Liming Intelligent Manufacturing Co Ltd
SHG:603048
|
China | CN¥315.09 Million |
|
Ce Link Ltd
SHE:300787
|
China | CN¥2.87 Billion |
|
Zhejiang Red Dragonfly Footwear Co Ltd
SHG:603116
|
China | CN¥862.29 Million |
|
Integrated Electronic Systems Lab Co Ltd
SHE:002339
|
China | CN¥2.12 Billion |
Liability Composition Analysis (2009–2025)
This chart breaks down TaiMed Biologics's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see 4147 total assets.
Liquidity & Leverage Metrics
TaiMed Biologics Total Liabilities Ratios Explained
TaiMed Biologics total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 15.48 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.22 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.18 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how TaiMed Biologics's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for TaiMed Biologics (2009–2025)
The table below shows the annual total liabilities of TaiMed Biologics from 2009 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | NT$953.05 Million ≈ $30.03 Million |
-2.39% |
| 2024-12-31 | NT$976.34 Million ≈ $30.76 Million |
-26.47% |
| 2023-12-31 | NT$1.33 Billion ≈ $41.83 Million |
-4.21% |
| 2022-12-31 | NT$1.39 Billion ≈ $43.67 Million |
-16.96% |
| 2021-12-31 | NT$1.67 Billion ≈ $52.59 Million |
-6.25% |
| 2020-12-31 | NT$1.78 Billion ≈ $56.09 Million |
+55.58% |
| 2019-12-31 | NT$1.14 Billion ≈ $36.05 Million |
+61.05% |
| 2018-12-31 | NT$710.55 Million ≈ $22.39 Million |
+237.22% |
| 2017-12-31 | NT$210.71 Million ≈ $6.64 Million |
+139.48% |
| 2016-12-31 | NT$87.99 Million ≈ $2.77 Million |
+230.38% |
| 2015-12-31 | NT$26.63 Million ≈ $839.05K |
-47.11% |
| 2014-12-31 | NT$50.35 Million ≈ $1.59 Million |
-11.66% |
| 2013-12-31 | NT$56.99 Million ≈ $1.80 Million |
+300.43% |
| 2012-12-31 | NT$14.23 Million ≈ $448.42K |
-6.04% |
| 2011-12-31 | NT$15.15 Million ≈ $477.25K |
-10.24% |
| 2010-12-31 | NT$16.88 Million ≈ $531.72K |
-11.55% |
| 2009-12-31 | NT$19.08 Million ≈ $601.16K |
-- |
About TaiMed Biologics
TaiMed Biologics Inc., a biotechnology company, develops, manufactures, and commercializes drugs for the treatment and prevention of infectious diseases. The company develops and markets Trogarzo IV infusion and Trogarzo IV push, a monoclonal antibody for HIV treatment. It is also developing TMB-365, a monoclonal antibody used for HIV treatment and prevention which has completed a phase-1 clinica… Read more